The UK subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) with effect from June 24, 2016. This is in connection with a number of serious breaches of the ABPI Code of Practice for the Pharmaceutical Industry.
The action is as a result of a complaint about an advisory board meeting held in Milan in February 2014 which was ruled to be in breach of the Code, including Clause 2 which deals with actions likely to bring discredit upon, or reduce confidence in, the pharmaceutical industry.
Following a second complaint and further action by the Prescription Medicines Code of Practice Authority (PMCPA), it also transpired that Astellas Europe had knowingly provided incorrect information to the PMCPA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze